Shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $24.67, but opened at $24.12. BioLife Solutions shares last traded at $23.98, with a volume of 128 shares traded.
Analyst Upgrades and Downgrades
Separately, Cowen decreased their price target on BioLife Solutions to $29.00 in a research report on Monday, August 15th. One analyst has rated the stock with a sell rating and three have given a buy rating to the stock. According to MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and an average target price of $31.25.
BioLife Solutions Stock Down 4.2 %
The company has a debt-to-equity ratio of 0.02, a current ratio of 3.55 and a quick ratio of 2.54. The company has a market cap of $950.52 million, a P/E ratio of -9.92 and a beta of 1.91. The stock has a 50-day moving average of $22.20 and a 200 day moving average of $18.45.
Insider Buying and Selling
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV acquired a new stake in shares of BioLife Solutions during the second quarter valued at about $36,000. Point72 Hong Kong Ltd acquired a new stake in shares of BioLife Solutions during the first quarter valued at about $36,000. Lazard Asset Management LLC acquired a new stake in shares of BioLife Solutions during the first quarter valued at about $45,000. Captrust Financial Advisors boosted its stake in shares of BioLife Solutions by 714.2% during the second quarter. Captrust Financial Advisors now owns 3,949 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 3,464 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its stake in shares of BioLife Solutions by 18.7% during the second quarter. Mutual of America Capital Management LLC now owns 5,128 shares of the medical equipment provider’s stock valued at $71,000 after purchasing an additional 808 shares in the last quarter. Institutional investors own 86.69% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.